Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.
Epistemonikos ID: 542649c458e294f4a7f71744d0eb3880da8fe28a
First added on: May 12, 2024